Epigallocatechin-3-gallate promotes apoptosis in human breast cancer T47D cells through down-regulation of PI3K/AKT and Telomerase

Pharmacological Reports

Volumn 69, Issue 5, 2017, Pages 924-928

  Moradzadeh, Maliheh ^a   Hosseini, Azar ^b   Erfanian, Saiedeh ^c   Rezaei, Hadi ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Breast cancer; Epigallocatechin 3 gallate; PI3K AKT signaling cascade; Telomerase

Indexed keywords

CASPASE 3; CASPASE 9; EPIGALLOCATECHIN GALLATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TAMOXIFEN; TELOMERASE REVERSE TRANSCRIPTASE; ANTIOXIDANT; CATECHIN; TELOMERASE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MTT ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; BREAST TUMOR; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTIOXIDANTS; APOPTOSIS; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TELOMERASE;

EID: 85021126716     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2017.04.008     Document Type: Article

References (32)

1. Mousavi, S.M., Gouya, M.M., Ramazani, R., Davanlou, M., Hajsadeghi, N., Seddighi, Z., Cancer incidence and mortality in Iran. Ann Oncol 20 (2009), 556–563.
2. Ahmad, N., Cheng, P., Mukhtar, H., Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 275 (2000), 328–334.
3. Xiang, L.-P., Wang, A., Ye, J.-H., Zheng, X.-Q., Polito, C.A., Lu, J.-L., et al. Suppressive effects of tea catechins on breast cancer. Nutrients, 8, 2016, 458.
4. Surh, Y.-J., Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3 (2003), 768–780.
5. Teiten, M.-H., Gaascht, F., Dicato, M., Diederich, M., Anticancer bioactivity of compounds from medicinal plants used in European medieval traditions. Biochem Pharmacol 86 (2013), 1239–1247.
6. Shu, L., Cheung, K.-L., Khor, T.O., Chen, C., Kong, A.-N., Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev 29 (2010), 483–502.
7. Saklani, A., Kutty, S.K., Plant-derived compounds in clinical trials. Drug Discov Today 13 (2008), 161–171.
8. Gupta, S., Hussain, T., Mukhtar, H., Molecular pathway for (−)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410 (2003), 177–185.
9. Thielecke, F., Boschmann, M., The potential role of green tea catechins in the prevention of the metabolic syndrome–a review. Phytochemistry 70 (2009), 11–24.
10. Xiao, J., Ho, C.T., Liong, E.C., Nanji, A.A., Leung, T.M., Lau, T.Y.H., et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 53 (2014), 187–199.
11. Yang, C.S., Landau, J.M., Huang, M.-T., Newmark, H.L., Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21 (2001), 381–406.
12. Li, M., Liu, J.-T., Pang, X.-M., Han, C.-J., Mao, J.-J., Epigallocatechin-3-gallate inhibits angiotensin II and interleukin-6-induced C-reactive protein production in macrophages. Pharmacol Rep 64 (2012), 912–918.
13. Zhou, J., Farah, B.L., Sinha, R.A., Wu, Y., Singh, B.K., Bay, B.-H., et al. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, stimulates hepatic autophagy and lipid clearance. PLoS One, 9, 2014, e87161.
14. Zeng, L., Holly, J.M., Perks, C.M., Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol, 5, 2014, 61.
15. Hosseini, A., Shafiee-Nick, R., Mousavi, S.H., Combination of Nigella sativa with Glycyrrhiza glabra and Zingiber officinale augments their protective effects on doxorubicin-induced toxicity in h9c2 cells. Iran J Basic Med Sci, 17, 2014, 993.
16. Pfaffl, M.W., Relative quantification. Real-time PCR 63 (2006), 63–82.
17. Sedghy, F., Sankian, M., Moghadam, M., Ghasemi, Z., Mahmoudi, M., Varasteh, A.-R., Impact of traffic-related air pollution on the expression of Platanus orientalis pollen allergens. Int J Biometeorol 61 (2017), 1–9.
18. Braicu, C., Pileczki, V., Pop, L., Petric, R.C., Chira, S., Pointiere, E., et al. Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model. PLoS One, 10, 2015, e0120936.
19. Meeran, S.M., Patel, S.N., Chan, T.-H., Tollefsbol, T.O., A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res 4 (2011), 1243–1254.
20. Belguise, K., Guo, S., Sonenshein, G.E., Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor α expression reversing invasive phenotype of breast cancer cells. Cancer Res 67 (2007), 5763–5770.
21. Chen, L., Lee, M.-J., Li, H., Yang, C.S., Absorption, distribution, and elimination of tea polyphenols in rats. Drug Metab Dispos 25 (1997), 1045–1050.
22. Isbrucker, R., Edwards, J., Wolz, E., Davidovich, A., Bausch, J., Safety studies on epigallocatechin gallate (EGCG) preparations Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 44 (2006), 636–650.
23. Dvorakova, K., Dorr, R.T., Valcic, S., Timmermann, B., Alberts, D.S., Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemother Pharmacol 43 (1999), 331–335.
24. Yang, C.S., Maliakal, P., Meng, X., Inhibition of carcinogenesis by tea*. Annu Rev Pharmacol Toxicol 42 (2002), 25–54.
25. Yeh, C., Chen, W., Chiang, C., Lin-Shiau, S., Lin, J., Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenom J 3 (2003), 267–276.
26. Zhang, G., Wang, Y., Zhang, Y., Wan, X., Li, J., Liu, K., et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med 12 (2012), 163–176.
27. Sartippour, M.R., Pietras, R., Marquez-Garban, D.C., Chen, H.-W., Heber, D., Henning, S.M., et al. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis 27 (2006), 2424–2433.
28. Sakata, M., Ikeda, T., Imoto, S., Jinno, H., Kitagawa, Y., Prevention of mammary carcinogenesis in C3H/OuJ mice by green tea and tamoxifen. Asian Pac J Cancer Prev 12 (2011), 567–571.
29. Scandlyn, M., Stuart, E., Somers-Edgar, T., Menzies, A., Rosengren, R., A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 99 (2008), 1056–1063.
30. Chisholm, K., Bray, B., Rosengren, R., Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 15 (2004), 889–897.
31. Qiao, J., Gu, C., Shang, W., Du, J., Yin, W., Zhu, M., et al. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem Toxicol 49 (2011), 1410–1415.
32. Shin, S.-C., Choi, J.-S., Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Anticancer Drugs 20 (2009), 584–588.